Compare Medpace Holdings Inc (MEDP) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs McCormick & Company, Incorporated — how do they compare? Medpace Holdings Inc trades at $530 (market cap $15.08B), while McCormick & Company, Incorporated trades at $52.01 (market cap $14.04B). The key difference: Medpace Holdings Inc and McCormick & Company, Incorporated are close in size by market cap, and McCormick & Company, Incorporated pays a 3.68% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | MKC | |
|---|---|---|
Market Cap | $15.08B | $14.04B |
Sector | Technology | Consumer Staples |
52-Week High | $620.59 | $72.81 |
52-Week Low | $308.88 | $45.60 |
Enterprise Value | $14.55B | $18.65B |
Dividend Yield | — | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
MKC trades at $52.35, up 1.26% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 21.91% net margin and 25.7% ROE, supported by recent Q2 2026 earnings beating estimates. Valuation appears attractive with a P/E of 8.69 and P/S of 1.9. The pending Unilever Foods deal, highlighted in recent news (The Motley Fool, 2026-07-07), could transform the business, though organic growth remains modest.
The outlook is cautiously optimistic with 36.7% of analysts rating it Buy and a consensus price target of $59.67 (13.9% upside). Key risks include soft consumer volumes and execution challenges from the Unilever integration. Positive cash flow projections for 2026 and a sustainable dividend enhance appeal, but investors should monitor volume trends and deal progress closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
